Antithymocyte globulin and cyclosporine in children with aplastic anemia: a developing country experience.
Abstract
BACKGROUND
Human leukocyte antigen-matched bone marrow transplant in the treatment of aplastic anemia is generally not feasible in developing
countries due to lack of resources and expertise and immunosuppressive therapy (IST) has been used as an alternative. This
study aims to report the long-term outcome of children with aplastic anemia treated with IST [antithymocyte globulin (ATG)
and cyclosporine] in our hospital.
PROCEDURE
Case files of children with aplastic anemia who received IST from January 2001 to November 2009 were reviewed.
RESULTS
Thirty-five patients with aplastic anemia (14 very severe aplastic anemia; 21 severe aplastic anemia) were given IST. Seven
patients expired within 3 months of therapy and were excluded. The analysis was done in 28 patients (24 male and 4 female;
12 very severe aplastic anemia and 16 severe aplastic anemia). The median age was 10 years (range, 5 to 12 y). Ten patients
achieved partial response and 4 patients complete response at 1 year with overall response rate of 50%. Three nonresponders
received a second course of ATG after 12 months out of which 2 responded. Hence, overall response including second course
was 16 (57%). Three patients relapsed after a median interval of 23 months. The median duration of follow-up of 16 responders
was 40 months (range, 15 to 119 mo). In the patients with long-term follow-up for >4 years (n = 7), all were surviving and
independent of transfusions.
CONCLUSIONS
In a developing country setting, IST with ATG and cyclosporine seems to be a good alternative treatment for aplastic anemia
in children.
Links
Authors
Sharma R, Chandra J, Sharma S, Pemde H, Singh V
Institution
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kalawati Saran Children's Hospital, Lady Hardinge Medical College, New Delhi, India. drrajnisharma@yahoo.com
Source
Journal of pediatric hematology/oncology 34:2 2012 Mar pg 93-5MeSH
Anemia, AplasticAntilymphocyte Serum
Child
Child, Preschool
Cyclosporine
Developing Countries
Female
Humans
Immunosuppressive Agents
India
Male
Treatment Outcome
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22278201
Log In

